CNS Pharmaceuticals Raises $22.5M, Stock Jumps 257%

CNS Pharmaceuticals announced a private placement of 650,000 shares and pre‑funded warrants raising about $22.5 million gross proceeds.
The financing, backed by ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners, is set to close around May 5, 2026.
Proceeds will fund acquisition of clinical‑stage assets, working capital, and out‑licensing of glioblastoma programs Berubicin and TPI‑287.
CEO Rami Levin said the capital positions CNS to execute its March 11, 2026 corporate strategy in a dynamic biotech environment.